Chardan Capital Weighs in on Adverum Biotechnologies, Inc.’s FY2025 Earnings (NASDAQ:ADVM)

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) – Investment analysts at Chardan Capital issued their FY2025 EPS estimates for Adverum Biotechnologies in a research note issued to investors on Tuesday, August 13th. Chardan Capital analyst D. Gataulin expects that the biotechnology company will post earnings of ($4.31) per share for the year. Chardan Capital currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Adverum Biotechnologies’ current full-year earnings is ($5.50) per share.

Adverum Biotechnologies (NASDAQ:ADVM) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.58.

A number of other equities research analysts have also recently weighed in on ADVM. Oppenheimer initiated coverage on shares of Adverum Biotechnologies in a research note on Tuesday, June 25th. They set an “outperform” rating and a $25.00 price objective on the stock. Truist Financial cut their price objective on shares of Adverum Biotechnologies from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Adverum Biotechnologies in a research note on Tuesday. StockNews.com upgraded shares of Adverum Biotechnologies from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Royal Bank of Canada cut their price objective on shares of Adverum Biotechnologies from $15.00 to $12.00 and set a “sector perform” rating on the stock in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.17.

Adverum Biotechnologies Stock Performance

Shares of ADVM opened at $6.82 on Thursday. Adverum Biotechnologies has a 1 year low of $6.38 and a 1 year high of $29.70. The company has a market cap of $141.56 million, a price-to-earnings ratio of -0.67 and a beta of 1.07. The firm has a fifty day moving average of $7.35 and a 200-day moving average of $11.50.

Insider Buying and Selling at Adverum Biotechnologies

In other Adverum Biotechnologies news, major shareholder Braden Michael Leonard purchased 85,800 shares of the business’s stock in a transaction on Tuesday, July 30th. The stock was bought at an average cost of $7.15 per share, with a total value of $613,470.00. Following the acquisition, the insider now owns 2,268,064 shares of the company’s stock, valued at $16,216,657.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Adverum Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of ADVM. AIGH Capital Management LLC lifted its stake in Adverum Biotechnologies by 139.6% during the fourth quarter. AIGH Capital Management LLC now owns 3,172,819 shares of the biotechnology company’s stock valued at $2,388,000 after buying an additional 1,848,834 shares in the last quarter. Vivo Capital LLC purchased a new stake in Adverum Biotechnologies during the first quarter valued at about $21,210,000. BML Capital Management LLC lifted its stake in Adverum Biotechnologies by 16.3% during the fourth quarter. BML Capital Management LLC now owns 4,554,252 shares of the biotechnology company’s stock valued at $3,428,000 after buying an additional 639,252 shares in the last quarter. Worth Venture Partners LLC lifted its stake in Adverum Biotechnologies by 136.5% during the fourth quarter. Worth Venture Partners LLC now owns 784,346 shares of the biotechnology company’s stock valued at $590,000 after buying an additional 452,678 shares in the last quarter. Finally, Avoro Capital Advisors LLC purchased a new stake in Adverum Biotechnologies during the first quarter valued at about $5,892,000. 48.17% of the stock is owned by institutional investors and hedge funds.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.